Neuronetics(STIM) - 2025 Q4 - Annual Results

Financial Performance - Neuronetics, Inc. reported preliminary unaudited financial results for Q4 and the full year 2025 on February 10, 2026[4]. - The company has a history of losses and is striving for sustainable profitability moving forward[6]. - There is an emphasis on maintaining positive cash flow and managing existing cash balances[6]. Product and Program Focus - The company is focusing on the performance of its NeuroStar Advanced Therapy System, which is critical for revenue generation[6]. - The company is working on the rollout of its Better Me Provider Program, aiming for timely execution[6]. Business Relationships and Risks - Neuronetics is currently assessing the impact of its transaction with Greenbrook TMS Inc. on business relationships and operational results[6]. - Neuronetics is facing risks related to competition, regulatory changes, and the demand for its products[6]. Investor Communication - Neuronetics is committed to updating its investors on forward-looking statements as new information becomes available[6]. - The press release detailing these results is filed as Exhibit 99.1 with the SEC[4]. Coverage and Reimbursement - The company is monitoring the availability of coverage and reimbursement from third-party payors for its treatments[6].